Subscribe to Search results

Local directors in Bradford, having discussed the Elstree protocols, did not want interim heat-treated product that would only likely be available two or three months and preferred to wait until April when "a better product is promised"

Published on:

In 1976, St George's Hospital had begun to shift away from cryoprecipitate and towards concentrate, predominantly commercial. Predominantly still cryoprecipitate used.

Published on:

In 1983, an annual return for St George's Hospital showed a significant shift to commercial concentrate (Armour) for both hospital and home treatment, with very little cryoprecipitate and some NHS concentrate

Published on:

The annual return for Guy's for 1982 shows that 229,675 units of concentrate were used in the treatment of 21 patients with Haemophilia A

Published on:

The annual return reported 160,575 units of concentrate were used in the treatment of 17 patients with Haemophilia .

Published on:

Cryoprecipitate was used for the treatment of Haemophilia A to an extent, but most treatment was with NHS concentrate.

Published on:

Dr Colvin did use substantial quantities of NHS Factor 8 (1,100,392 units) as well as 148,540 units of cryoprecipitate and 388,654 units of commercial concentrate (Koate,
Factorate, Hemofil and Kryobulin) for the treatment of 78 patients with Haemophilia A.

Published on:

It appeared that substantial quantities of NHS Factor 8, cryoprecipitate and commercial concentrate were used for the treatment of patients.

Published on:

A reduction in the purchase of commercial concentrate in 1983 was due to an increase in supply of NHS material demonstrating Dr Colvin's intent to minimise risk where and when it was sensible to do so.

Published on:

In reference to the risks of AIDS in haemophilia services, possible complications in treatment were described as "Plasma product-transmitted disease, particularly hepatitis and (possibly) the acquired immune deficiency syndrome (AIDS)"

Published on:

Dr Colvin wrote that they knew little about AIDS at this time. The health service should not "spurn" commercial concentrate as they must stay aware of the risks associated with NHS material.

Published on:

It was stated that "until a positive test for AIDS and/or a vaccine is developed it should be policy to avoid use of blood products except for essential treatments and to use cryoprecipitate or plasma instead of FVIII Concentrate whenever possible."

Published on:

Dr Colvin reported that, at London Hospital Haemophilia Centre, there were 41 patients infected with HIV, of whom 31 had severe Haemophilia A, 9 had moderate/mild Haemophilia A and 1 had Haemophilia B. He recalled three children who were infected with HIV from their treatment and one partner of a patient who was infected.

Published on:

Whilst the volume of NHS concentrate used at the Leeds Haemophilia Centre increased in 1983, a very substantial amount of commercial concentrate continued to be used.

Published on:

1,497,585 units of NHS Factor 8 and 1,715,894 units of commercial concentrates were used at the Leeds Haemophilia Centre.

Published on:

Small amounts of cryoprecipitate were used with NHS concentrate and commercial concentrates were used in substantial amounts at the Leeds Haemophilia Centre.

Published on:

At a Mersey RTC meeting, there was no discussion at all about the issue of AIDS.

Published on:

In Liverpool, the use of NHS concentrate increased in 1983.

Published on:

In Liverpool, the use of NHS concentrate increased in 1984.

Published on:

Dr McVerry indicated that he had no awareness of AIDS until the September 1982 UKHCDO meeting. Up to mid 1984, there was no proven association with blood products, although he said it was reasonably clear there was a real risk at the end of 1983 or beginning of 1984.

Published on: